The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415. https://doi.org/10.1016/S2468-1253(21)00472-6.

Article  Google Scholar 

World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021 Accountability for the global health sector strategies 2016–2021: actions for impact. Geneva: World Health Organization; 2021. p. 2021.

Google Scholar 

World Health Organization. Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low and middle-income countries. Global progress report 2020. Geneva: World Health Organization; 2021.

Google Scholar 

Younossi ZM, Tanaka A, Eguchi Y, Lim YS, Yu ML, Kawada N, et al. The impact of hepatitis C virus outside the liver: evidence from Asia. Liver Int. 2017;37(2):159–72. https://doi.org/10.1111/liv.13272.

Article  PubMed  Google Scholar 

World Health Organization. Combating hepatitis B and C to reach elimination by 2030. Geneva: World Health Organization; 2016.

Google Scholar 

World Health Organization. Global health sector strategy on viral hepatitis 2016–2021. Geneva: World Health Organization. 2016. https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/. Accessed 24 Feb 2023.

World Health Organization. Global hepatitis report 2017. Geneva: World Health Organization; 2017.

Google Scholar 

Burki T. Eliminating hepatitis C. Lancet Infect Dis. 2019;19(3):246–7. https://doi.org/10.1016/S1473-3099(19)30073-8.

Article  PubMed  Google Scholar 

Waked I, Esmat G, Elsharkawy A, El-Serafy M, Abdel-Razek W, Ghalab R, et al. Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med. 2020;382(12):1166–74. https://doi.org/10.1056/NEJMsr1912628.

Article  PubMed  Google Scholar 

Averhoff F, Shadaker S, Gamkrelidze A, Kuchuloria T, Gvinjilia L, Getia V, et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J Hepatol. 2020;72(4):680–7. https://doi.org/10.1016/j.jhep.2019.11.019.

Article  CAS  PubMed  Google Scholar 

Yousafzai MT, Bajis S, Alavi M, Grebely J, Dore GJ, Hajarizadeh B. Global cascade of care for chronic hepatitis C virus infection: a systematic review and meta-analysis. J Viral Hepat. 2021;28(10):1340–54. https://doi.org/10.1111/jvh.13574.

Article  PubMed  Google Scholar 

World Health Organization. Hepatitis B and C in the WHO Western Pacific Region. https://www.who.int/westernpacific/health-topics/hepatitis/regional-hepatitis-data. Accessed 24 Feb 2023.

Song Y, Li Y, Cheng H, Du X, Mi J, Le LV, et al. Eliminate hepatitis C as a public health threat: a narrative review of strategies, gaps, and opportunities for China. Infect Dis Ther. 2022;11(4):1427–42. https://doi.org/10.1007/s40121-022-00670-4.

Article  PubMed  PubMed Central  Google Scholar 

Ding G, Ye S, Hei F, Lian Q, Pei X, Bai J, et al. Sentinel surveillance of viral hepatitis C in China 2016–2017. Chin J Epidemiol. 2019;40(1):41–5. https://doi.org/10.3760/cma.j.issn.0254-6450.2019.01.009. (in Chinese).

Article  CAS  Google Scholar 

Ding G, Pang L, Wang X, Shao Y, Hei F. Characteristic of baseline hepatitis C in sentinel hospitals 2017–2019. Chin J Hepatol. 2020;28(10):844–9. https://doi.org/10.3760/cma.j.cn50113-20200901-00492. (in Chinese).

Article  CAS  Google Scholar 

China CDC. NCAIDS. Prevention and treatment of hepatitis C in sentinel hospitals. (2020–07–07). https://ncaids.chinacdc.cn/fzyw_10256/bgfz/202007/t20200715_217793.htm. Accessed 24 Feb 2023.

Wu J, Cao L, Zhu X, Wang F, Lu C. Impact of capitation payment for HCV treatment not covered by Tianjin basic health insurance. Chin Medical Insur. 2019;12(11):38–44. https://doi.org/10.19546/j.issn.1674-3830.2019.11.009. (in Chinese).

Article  Google Scholar 

Wen J, Gao Y, Ding G, Ye S, Hei F, Pang L. Current status of diagnosis and treatment of hepatitis C in hospitals. Chin AIDS & STD. 2018;24(06):581–4. https://doi.org/10.13419/j.cnki.aids.2018.06.13. (in Chinese).

Article  Google Scholar 

Yang X, Xu Z, Mei Y, Lin G, Wei J, Shao X, et al. Barriers to hepatitis C virus treatment in Guangdong Province. Ann Palliat Med. 2019;8(5):640–4. https://doi.org/10.21037/apm.2019.11.20.

Article  PubMed  Google Scholar 

He N, Hao S, Feng G, Gao J, Kong F, Ren Z, et al. Analysis of the influencing factors of the diagnosis and treatment of hepatitis C in hospitals on the elimination strategy in the hospital. Chin Hepatology. 2021;29(11):1053–8. https://doi.org/10.3760/cma.j.cn501113-20210119-00034. (in Chinese).

Article  CAS  Google Scholar 

Sun J, Luo R. Application of diabetic medications and essential medicines in Chinese hospitals. Chin Pharm. 2016;27(24):3313–9. https://doi.org/10.6039/j.issn.1001-0408.2016.24.01. (in Chinese).

Article  Google Scholar 

Liu J, Bratton E, Yu X, Ladbury C, Wagner J, West H, et al. Patterns of care in maintenance therapy in US Patients undergoing definitive chemoradiation for stage 3 non-small cell lung cancer (NSCLC). Am J Clin Oncol. 2022;45(2):49–54. https://doi.org/10.1097/COC.0000000000000886.

Article  CAS  PubMed  Google Scholar 

van den Boom L, Kostev K. Patterns of insulin therapy and insulin daily doses in children and adolescents with type I diabetes in Germany. Diabetes Obes Metab. 2022;24(2):296–301. https://doi.org/10.1111/dom.14581.

Article  CAS  PubMed  Google Scholar 

Zemedikun DT, Chandan JS, Raindi D, Rajgor AD, Gokhale KM, Thomas T, et al. Burden of chronic diseases associated with periodontal diseases: a retrospective cohort study using UK primary care data. BMJ Open. 2021;11(12):e048296. https://doi.org/10.1136/bmjopen-2020-048296.

Article  PubMed  PubMed Central  Google Scholar 

Khraishi M, Ivanovic J, Zhang Y, Millson B, Brabant MJ, Charland K, et al. Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data. Clin Rheumatol. 2018;37(9):2351–60. https://doi.org/10.1007/s10067-018-4141-z.

Article  PubMed  Google Scholar 

Sun J, Ren L, Wirtz V. How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics? J Med Econ. 2016;19(9):881–8. https://doi.org/10.1080/13696998.2016.1181641.

Article  PubMed  Google Scholar 

Diao Y, Qian J, Liu Y, Zhou Y, Wang Y, Ma H, et al. How government insurance coverage changed the utilization and affordability of expensive targeted anti-cancer medicines in China: an interrupted time-series study. J Glob Health. 2019;9(2):020702. https://doi.org/10.7189/jogh.09.020702.

Article  PubMed  Google Scholar 

Huang Z, Su X, Diao Y, Sun J, Liu Y. Use of opioid analgesics in cancer treatment and personal economic burden in different regions of China. J Pharmacoepidem. 2019;8(6):389–94. https://doi.org/10.19960/j.cnki.issn1005-0698.2019.06.009. (in Chinese).

Article  Google Scholar 

Huang Z, Su X, Diao Y, Liu S, Zhi M, Geng S, et al. Clinical consumption of opioid analgesics in China: a retrospective analysis of the national and regional data 2006–2016. J Pain Symptom Manag. 2020;59(4):829–35. https://doi.org/10.1016/j.jpainsymman.2019.11.003.

Article  CAS  Google Scholar 

National Medical Products Administration. Center for Drug Evaluation. Information for Public Access of the Marketed Medicines. https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d. Accessed 24 Feb 2023 (In Chinese).

Chinese Medical Association Hepatology Branch, Chinese Medical Association Infectious Diseases Branch. Guidelines for the prevention and treatment of hepatitis C (2019 ed.). Chin J Infect Dis. 2020;038(001):9–28 (In Chinese).

Google Scholar 

National Health Commission. Notifiable infectious disease report. http://www.nhc.gov.cn/jkj/s2907/new_list.shtml?tdsourcetag=s_pcqq_aiomsg. Accessed 27 Feb 2023 (In Chinese).

National Bureau of Statistics of China. China Statistical Yearbook. 2021. http://www.stats.gov.cn/tjsj/ndsj/2021/indexch.htm. Accessed 27 Feb 2023 (In Chinese).

Yearbook China. China Health Statistics Yearbook. 2021. https://www.yearbookchina.com/navibooklist-n3022013080-1.html. Accessed 27 Feb 2023 (In Chinese).

China National Health Development Research Center. China National Health Accounts Report. 2021. Beijing: CNHDRC (In Chinese).

Google Scholar 

Lennon H, Kelly S, Sperrin M, Buchan I, Cross AJ, Leitzmann M, et al. Framework to construct and interpret latent class trajectory modelling. BMJ Open. 2018;8:e020683. https://doi.org/10.1136/bmjopen-2017-020683.

Article  PubMed  PubMed Central  Google Scholar 

Mirza SS, Wolters FJ, Swanson SA, Koudstaal PJ, Hofman A, Tiemeier H, et al. 10-year trajectories of depressive symptoms and risk of dementia: a population-based study. Lancet Psychit. 2016;3(7):628–35. https://doi.org/10.1016/S2215-0366(16)00097-3.

Article  Google Scholar 

National Medical Products Administration. Dalatavir hydrochloride tablets and asulivir softgels are approved by NMPC. https://www.nmpa.gov.cn/yaopin/ypjgdt/20170428101301734.html. Accessed 24 Feb 2023 (In Chinese).

Ju X, Zhang X. Analysis of People’s willingness to participate in medication therapy management and the influencing factors. Chin J Hospital Manag. 2019;39(5):42–4 (In Chinese).

Google Scholar 

World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. https://www.who.int/publications/i/item/9789240053779. Accessed 24 Feb 2023.

Doyle JS, Scott N, Sacks-Davis R, Pedrana AE, Thompson AJ, Hellard ME. Eliminate Hepatitis C Partnership. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia. Aliment Pharmacol Ther. 2019;49(9):1223–9. https://doi.org/10.1111/apt.15210.

Article  PubMed  Google Scholar 

Zhuang H, Wei L, Wang G. Health China 2030. White Paper on Action to Eliminate the Threat of Hepatitis C 2030. 2022. http://liver.org.cn/portal.php?mod=view&aid=776. Accessed 24 Feb 2023 (In Chinese).

Wu W, Zhou L. Utilization of medicines under national price negotiation in hospitals. Strait Pharmacy. 2020;32(3):170–1. https://doi.org/10.3969/j.issn.1006-3765.2020.03.064.

Article  Google Scholar 

Tianjin Municipal Human Resources and Social Security Bureau. Notice on the Pilot capitated payment program for outpatient care of hepatitis C. http://hrss.tj.gov.cn/zhengwugongkai/zhengcezhinan/zxwjnew/202012/t20201206_4492409.html. Accessed 24 Feb 2023 (In Chinese).

Xinmin Evening News. World Hepatitis Day| 219 medical institutions in Shanghai provide hepatitis care. https://baijiahao.baidu.com/s?id=1739555740739544168&wfr=spider&for=pc. Accessed 24 Feb 2023(In Chinese).

Shanghai Municipal Health Commission. Notice on "Shanghai Family Doctor Contract Service Program (2020 Edition)" https://wsjkw.sh.gov.cn/jcws2/20200529/a8a87c1294d9413a8b41754056bd59aa.html. Accessed 24 Feb 2023 (In Chinese).

Ningbo Healthcare Security Administration. Public Health Action Plan to Eliminate Hepatitis C launched in Ningbo. http://www.ningbo.gov.cn/art/2019/12/11/art_1229096033_52669279.html. Accessed 24 Feb 2023 (In Chinese).

World Health Organization. World Hepatitis Day 2022 Bringing hepatitis care closer to you. https://www.who.int/campaigns/world-hepatitis-day/2022. Accessed 24 Feb 2023.

World Health Organization. Global HIV, Hepatitis and Sexually Transmitted Infections Program. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/full-final-who-ghss-hiv-vh-sti_1-june2022.pdf?sfvrsn=7c074b36_13&download=true. Accessed 24 Feb 2023.

Chan PL, Le LV, Ishikawa N, Easterbrook P. Regional progress towards hepatitis C elimination in the Western Pacific Region, 2015–2020. Glob Health Med. 2021;3(5):253–61. https://doi.org/10.35772/ghm.2021.01065.

Article  PubMed  PubMed Central  Google Scholar 

Sun J, Cheng H, Hassan MRA, Chan HK, Piedagnel JM. What China can learn from Malaysia to achieve the goal of “eliminate hepatitis C as a public health threat” by 2030—a narrative review. Lancet Reg Health West Pac. 2021;16:100261. https://doi.org/10.1016/j.lanwpc.2021.100261.

Article  PubMed  PubMed Central  Google Scholar 

Seoane Blanco L, Soto Sánchez J, Sierra Dorado G, Parapar Álvarez L, Crespo Sánchez M, Sánchez Domínguez L, et al. Active search for hepatitis C patients in primary care. Rev Esp Enferm Dig. 2021;113(12):820–4. https://doi.org/10.17235/reed.2021.8067/2021.

Article  PubMed  Google Scholar 

Jarvis H, Whiteley D. Eliminating hepatitis C: time to embrace primary care’s critical role? Br J Gen Pract. 2021;71(707):250–1. https://doi.org/10.3399/bjgp21X715901.

Article  PubMed  PubMed